WATCHMAN FLX Pro left atrial appendage closure device. Credit: Boston Scientific Corporation / MultiVu.

Boston Scientific has received approval from the US Food and Drug Administration (FDA) for its WATCHMAN FLX Pro left atrial appendage closure (LAAC) device.

The latest-generation device leverages the established safety and procedural performance of the WATCHMAN FLX LAAC device, which received approval in July 2020.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It features an advanced coating designed to lower device-related thrombosis while promoting rapid, controlled healing and endothelisation of the device surface.

The device also has visualisation markers, which help advance device placement for optimal sealing around the LAA.

The company offers a new 40mm option for the device, helping physicians treat a wide range of anatomies with WATCHMAN technology.

See Also:

Meanwhile, the new device is being assessed in the single-centre premarket WATCHMAN FLX Pro CT study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study utilises multiple imaging modalities for evaluating device tissue coverage after the procedure and its potential connection to clinical outcomes.

The device will undergo additional assessment in the post-market HEAL-LAA study, set to begin in the next few weeks.

This study will monitor the results of approximately 1,000 patients with NVAF who have received the technology at 60 different sites in the US.

Boston Scientific Cardiology group president Joe Fitzgerald said: “We are pleased to introduce US clinicians to our newest LAAC technology, which is designed to enhance post-procedural healing, improve the precision of WATCHMAN FLX Pro implants and expand the size range of treatable appendages.

“These enhancements to our WATCHMAN FLX technology will enable efficiency during implant procedures and allow physicians to optimise treatment for their patients.”